Adult Dermatomyositis: What Is the Treatment When Skin Disease Is Refractory to Glucocorticoids and csDMARDs?
In some adults with dermatomyositis, skin manifestations remain active despite treatment with glucocorticoids and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). This refractory skin disease requires a reassessment of the therapeutic approach.
Clinical scenario: Skin disease in adult dermatomyositis that remains active despite a glucocorticoid- and csDMARD-based immunosuppressive regimen.
Therapeutic Approach
For this refractory scenario, specific advanced immunotherapy is considered — the full protocol defines which therapies apply and how they are selected.
The complete evidence-based regimen, including all options and decision criteria, is available in the structured protocol below.
References
DOI: 10.1093/rheumatology/keac115
- Rituximab is to be considered for the treatment of skin disease refractory to glucocorticoid/csDMARD-based immunosuppression.
- IVIG should be considered for the treatment of skin disease refractory to glucocorticoid/csDMARD-based immunosuppression.
View source ↗